USV PRIVATE LIMITED

usvindia.com

We are a 55 year old leading healthcare company which began as a joint venture with USV&P Inc. USA, a subsidiary of Revlon. Our product offering today includes Active Pharmaceutical Ingredients (APIs), Fixed Dosages Formulations (FDF), Peptides, Biosimilars and Injectables. These are manufactured in our cGMP compliant plants located in India. We market our products globally to 75 countries. In the financial year 2015-16, our total income was Rs 25,445 million. Our Indian business contributed 82% to the revenue and the rest was from export of APIs and Finished Dosages.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

SPECIFIC BIOLOGICS INC. ANNOUNCES THERAPEUTIC DEVELOPMENT AWARD FROM THE CYSTIC FIBROSIS FOUNDATION

Specific Biologics Inc. | December 08, 2021

news image

Specific Biologics Inc. an early-stage biotechnology company developing novel gene editing technologies, announced that it will receive more than US$527,000 to support the preclinical development of its Dualase™ gene editing platform to target a set of cystic fibrosis -causing nonsense mutations where patients currently have fewer therapeutic options available. "Incredible advancements in the treatment of cystic fibrosis have been made since the id...

Read More

Cell and Gene Therapy

BEIGENE INITIATES FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL OF INVESTIGATIONAL TYK2 INHIBITOR BGB-23339

BeiGene | November 23, 2021

news image

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, announced that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor internally developed by BeiGene scientists. TYK2 is a member of the JAK family and functions as a critical mediator in cytokine signaling pathways implicated in multiple immune-mediated disorders, such as psor...

Read More

Cell and Gene Therapy, Medical

SYNTHEGO AND BIT.BIO EXPAND STRATEGIC PARTNERSHIP TO BUILD A PLATFORM FOR THE DEVELOPMENT OF SAFER AND MORE EFFICIENT GENETIC ENGINEERING OF HUMAN

prnewswire | August 25, 2023

news image

Synthego, a leading provider of industrialized genome editing solutions that accelerate discovery to clinic journey, and bit.bio, the company coding human cells for novel cures, today announced a strategic partnership to build a platform centered on the implementation of synthetic circuitry in cells for therapeutic application. bit.bio is building a pipeline of cell therapies focused on areas of unmet clinical need. The partnership will apply Synthego's expertise in gene edi...

Read More

MedTech

FLAMINGO THERAPEUTICS EXPANDS ALLIANCE WITH IONIS PHARMACEUTICALS TO DEVELOP RNA-TARGETED THERAPIES FOR ONCOLOGY

Flamingo Therapeutics, Inc. | September 09, 2021

news image

Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to treat various forms of cancer. This alliance is an expansion of an existing collaboration with Ionis on the FLAME™ discovery engine, following Flamingo's Series A financing in 2020. The agreement and discovery alliance will leverage Flamingo's de...

Read More
news image

Cell and Gene Therapy

SPECIFIC BIOLOGICS INC. ANNOUNCES THERAPEUTIC DEVELOPMENT AWARD FROM THE CYSTIC FIBROSIS FOUNDATION

Specific Biologics Inc. | December 08, 2021

Specific Biologics Inc. an early-stage biotechnology company developing novel gene editing technologies, announced that it will receive more than US$527,000 to support the preclinical development of its Dualase™ gene editing platform to target a set of cystic fibrosis -causing nonsense mutations where patients currently have fewer therapeutic options available. "Incredible advancements in the treatment of cystic fibrosis have been made since the id...

Read More
news image

Cell and Gene Therapy

BEIGENE INITIATES FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL OF INVESTIGATIONAL TYK2 INHIBITOR BGB-23339

BeiGene | November 23, 2021

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, announced that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor internally developed by BeiGene scientists. TYK2 is a member of the JAK family and functions as a critical mediator in cytokine signaling pathways implicated in multiple immune-mediated disorders, such as psor...

Read More
news image

Cell and Gene Therapy, Medical

SYNTHEGO AND BIT.BIO EXPAND STRATEGIC PARTNERSHIP TO BUILD A PLATFORM FOR THE DEVELOPMENT OF SAFER AND MORE EFFICIENT GENETIC ENGINEERING OF HUMAN

prnewswire | August 25, 2023

Synthego, a leading provider of industrialized genome editing solutions that accelerate discovery to clinic journey, and bit.bio, the company coding human cells for novel cures, today announced a strategic partnership to build a platform centered on the implementation of synthetic circuitry in cells for therapeutic application. bit.bio is building a pipeline of cell therapies focused on areas of unmet clinical need. The partnership will apply Synthego's expertise in gene edi...

Read More
news image

MedTech

FLAMINGO THERAPEUTICS EXPANDS ALLIANCE WITH IONIS PHARMACEUTICALS TO DEVELOP RNA-TARGETED THERAPIES FOR ONCOLOGY

Flamingo Therapeutics, Inc. | September 09, 2021

Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to treat various forms of cancer. This alliance is an expansion of an existing collaboration with Ionis on the FLAME™ discovery engine, following Flamingo's Series A financing in 2020. The agreement and discovery alliance will leverage Flamingo's de...

Read More

Resources

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

resource image

Cell and Gene Therapy

VIA Thaw™ automated dry thawer

Video

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us